Heparin mimetics: Novel non-anticoagulant compounds to promote CNS repair.

肝素模拟物:促进中枢神经系统修复的新型非抗凝化合物。

基本信息

  • 批准号:
    MR/V00381X/1
  • 负责人:
  • 金额:
    $ 51.29万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2020
  • 资助国家:
    英国
  • 起止时间:
    2020 至 无数据
  • 项目状态:
    已结题

项目摘要

Damage to the brain and spinal cord (together known as the central nervous system; CNS) is notoriously difficult to repair. In a disease such as multiple sclerosis damage occurs in which nerve processes lose their protective insulation wrapping (becoming "demyelinated", leading to faulty nerve signalling) and scarring forms in the tissue (called "astrogliosis", which prevents nerve regrowth). Current therapeutics tend to focus solely on altered immune responses, which cause damage, but not on other tissue changes. Repair is multifactorial and very complex, requiring a damping down of the immune response and scar tissue formation, as well as the promotion of re-insulation (myelination) and nerve outgrowth. Specialised sugar molecules that reside around the injury site, known as heparan sulphates (HS), carry out the regulation of many cellular functions required for repair. HS has varied patterns of sulphate groups on their surface, which by virtue of their number and position on the molecule can make neural cells carry out different types of functions. To study how HS works, we use chemical mimics of HS called heparin mimetics (mHeps). These mHeps are modified forms of the blood-thinning drug heparin but can be made chemically with altered amounts and positions of the sulphate groups. Using several assays in a Petri dish we have found that mHeps with a low number of sulphate groups promote remyelination, nerve process outgrowth and dampen down the scarring reactions. We also have some evidence that they can have a beneficial effect in animal models of disease, especially promoting remyelination, modulation of the immune response as well as general health (with less animal weight loss). For this reason, we now aim to carry out detailed experiments on the repair efficacy of a low sulphated mHep using an animal model of demyelination. We aim to:i) Confirm dosage, concentration and optimal molecular weight form of mHep7.ii) Confirm preliminary data that mHep7 (comparing two MW forms) can promote repair in two pre-clinical animal models classically used to study CNS injury.iii) Identify how the compounds work (ie. their mechanism-of-action), focusing on the immune response (which can enter the CNS and damage cells), weight gain (mHeps appear to promote CNS repair and animals appear healthier with less weight loss) and the integrity of the blood-brain barrier (BBB). The BBB prevents materials from the blood entering the brain. In disease, this can be leaky and allow the immune system to enter the brain, which can be harmful.Overall we aim to show that low sulphated mHeps are potential new drugs to promote CNS repair by having a multi-modal effect on several key cellular properties induced after injury/disease.
众所周知,大脑和脊髓(统称为中枢神经系统; CNS)的损伤很难修复。在诸如多发性硬化症的疾病中,神经过程失去其保护性绝缘包裹(变得“脱髓鞘”,导致神经信号传导错误)并且在组织中形成瘢痕(称为“星形胶质细胞增生”,其阻止神经再生)。目前的治疗方法往往只关注引起损伤的免疫反应的改变,而不关注其他组织的变化。修复是多因素的,非常复杂,需要抑制免疫反应和瘢痕组织形成,以及促进再绝缘(髓鞘形成)和神经生长。位于损伤部位周围的专门的糖分子,称为硫酸乙酰肝素(HS),对修复所需的许多细胞功能进行调节。HS在其表面上具有不同的硫酸基团模式,凭借它们在分子上的数量和位置,可以使神经细胞执行不同类型的功能。为了研究HS如何工作,我们使用称为肝素模拟物(mHeps)的HS化学模拟物。这些mHep是血液稀释药物肝素的改良形式,但可以通过改变硫酸基团的数量和位置来化学制备。在皮氏培养皿中使用几种测定,我们发现具有少量硫酸盐基团的mHep促进髓鞘再生、神经突起生长并抑制瘢痕形成反应。我们也有一些证据表明,它们可以在疾病的动物模型中产生有益的影响,特别是促进髓鞘再生,调节免疫反应以及一般健康(动物体重减轻较少)。出于这个原因,我们现在的目标是使用脱髓鞘的动物模型对低硫酸化mHep的修复功效进行详细的实验。我们的目的是:i)确认mHep 7的剂量、浓度和最佳分子量形式。ii)确认mHep 7(比较两种MW形式)可以促进经典地用于研究CNS损伤的两种临床前动物模型中的修复的初步数据。它们的作用机制),重点是免疫反应(它可以进入中枢神经系统和损伤细胞),体重增加(mHep似乎促进中枢神经系统修复,动物看起来更健康,体重减轻较少)和血脑屏障(BBB)的完整性。血脑屏障阻止血液中的物质进入大脑。在疾病中,这可能是泄漏的,并允许免疫系统进入大脑,这可能是有害的。总体而言,我们的目标是表明,低硫酸化mHep是潜在的新药物,通过对损伤/疾病后诱导的几个关键细胞特性具有多模式效应,以促进CNS修复。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Validation of Recombinant Heparan Sulphate Reagents for CNS Repair.
  • DOI:
    10.3390/biology12030407
  • 发表时间:
    2023-03-04
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
  • 通讯作者:
Human olfactory mesenchymal stromal cell transplantation ameliorates experimental autoimmune encephalomyelitis revealing an inhibitory role for IL16 on myelination.
人类嗅觉间充质基质细胞移植可以改善实验性自身免疫性脑脊髓炎,揭示了IL16在髓鞘中的抑制作用。
  • DOI:
    10.1186/s40478-022-01316-9
  • 发表时间:
    2022-01-29
  • 期刊:
  • 影响因子:
    7.1
  • 作者:
    Lindsay SL;Molęda AM;MacLellan LM;Keh SM;McElroy DE;Linington C;Goodyear CS;Barnett SC
  • 通讯作者:
    Barnett SC
Therapeutic Potential of Niche-Specific Mesenchymal Stromal Cells for Spinal Cord Injury Repair.
  • DOI:
    10.3390/cells10040901
  • 发表时间:
    2021-04-14
  • 期刊:
  • 影响因子:
    6
  • 作者:
    Lindsay SL;Barnett SC
  • 通讯作者:
    Barnett SC
Low sulfated heparan sulfate mimetic differentially affects repair in immune-mediated and toxin-induced experimental models of demyelination
  • DOI:
    10.1002/glia.24363
  • 发表时间:
    2023-03-21
  • 期刊:
  • 影响因子:
    6.2
  • 作者:
    Lindsay,Susan L.;McCanney,George A.;Barnett,Susan C.
  • 通讯作者:
    Barnett,Susan C.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Susan Barnett其他文献

From Discovery to Clinical Testing(Design Platforms of Nanocapsules for Human Therapeutics or Vaccines)
从发现到临床测试(用于人类治疗或疫苗的纳米胶囊设计平台)
  • DOI:
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Masaaki Kawano;Li Xing;Kit S. Lam;Hiroshi Handa;Tatsuo Miyamura;Susan Barnett;Indresh K. Srivastava;and R. Holland Cheng Jhon Wiley & Sons.
  • 通讯作者:
    and R. Holland Cheng Jhon Wiley & Sons.
Resolution of sustained narrow complex ventricular tachycardia and tachycardia-induced cardiomyopathy in a Quarter Horse following quinidine therapy
  • DOI:
    10.1016/j.jvc.2012.05.004
  • 发表时间:
    2012-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Joshua A. Stern;Yamir Reina Doreste;Susan Barnett;Sunshine M. Lahmers;Ryan D. Baumwart;Kathy K. Seino;John D. Bonagura
  • 通讯作者:
    John D. Bonagura

Susan Barnett的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Susan Barnett', 18)}}的其他基金

Novel strategies for promoting CNS repair through manipulation of FGF signalling and heparan sulphate proteoglycans
通过操纵 FGF 信号和硫酸乙酰肝素蛋白聚糖促进 CNS 修复的新策略
  • 批准号:
    MR/K014366/1
  • 财政年份:
    2013
  • 资助金额:
    $ 51.29万
  • 项目类别:
    Research Grant
Does cellular niche affect the repair potential of mesenchymal stem cells; implications for spinal cord injury?
细胞生态位是否影响间充质干细胞的修复潜力?
  • 批准号:
    MR/J004731/1
  • 财政年份:
    2012
  • 资助金额:
    $ 51.29万
  • 项目类别:
    Research Grant
The development of an in vitro model of CNS injury to identify factors which promote repair.
开发中枢神经系统损伤的体外模型,以确定促进修复的因素。
  • 批准号:
    G0800572/1
  • 财政年份:
    2009
  • 资助金额:
    $ 51.29万
  • 项目类别:
    Research Grant
Micro engineered 3D constructs for CNS repair
用于中枢神经系统修复的微工程 3D 结构
  • 批准号:
    BB/G004706/1
  • 财政年份:
    2009
  • 资助金额:
    $ 51.29万
  • 项目类别:
    Research Grant

相似国自然基金

新的有机小分子BH3 模拟物的分子特征和构效关系
  • 批准号:
    30772622
  • 批准年份:
    2007
  • 资助金额:
    25.0 万元
  • 项目类别:
    面上项目

相似海外基金

Probing functional HIV-1 envelope glycoprotein conformations with novel potent CD4-mimetic compounds
用新型有效的 CD4 模拟化合物探测功能性 HIV-1 包膜糖蛋白构象
  • 批准号:
    10762703
  • 财政年份:
    2023
  • 资助金额:
    $ 51.29万
  • 项目类别:
Troponin I phosphorylation as a novel novel cardiac inotrope
肌钙蛋白 I 磷酸化作为一种​​新型强心剂
  • 批准号:
    10660193
  • 财政年份:
    2023
  • 资助金额:
    $ 51.29万
  • 项目类别:
Novel Drug Delivery Platform as Medical Countermeasure for treatment of Gastrointestinal Radiation Damage
新型给药平台作为治疗胃肠道辐射损伤的医学对策
  • 批准号:
    10698637
  • 财政年份:
    2023
  • 资助金额:
    $ 51.29万
  • 项目类别:
A Novel Bone Marrow Transplantation Approach for Sickle Cell Disease Using Targeted Marrow Irradiation
使用靶向骨髓照射治疗镰状细胞病的新型骨髓移植方法
  • 批准号:
    10737358
  • 财政年份:
    2023
  • 资助金额:
    $ 51.29万
  • 项目类别:
A novel bioengineering approach to restoring permanent periodontal inflammatory bone loss
一种恢复永久性牙周炎性骨质流失的新型生物工程方法
  • 批准号:
    10734465
  • 财政年份:
    2023
  • 资助金额:
    $ 51.29万
  • 项目类别:
Elucidation of Tumor Resistance Mechanisms in Tuberous Sclerosis Complex-Associated Renal Angiomyolipoma for the Design of Novel Nanotherapies
阐明结节性硬化症相关肾血管平滑肌脂肪瘤的肿瘤抵抗机制,用于设计新型纳米疗法
  • 批准号:
    10585048
  • 财政年份:
    2023
  • 资助金额:
    $ 51.29万
  • 项目类别:
Engineering a Novel Bio-Scaffold for Hepatic Tissue Restoration and Drug Screening
设计用于肝组织恢复和药物筛选的新型生物支架
  • 批准号:
    10412230
  • 财政年份:
    2022
  • 资助金额:
    $ 51.29万
  • 项目类别:
A Novel Anti-inflammatory and Anti-oxidant Therapy for Treating Non-healing Diabetic Foot Ulcers
一种治疗不愈合糖尿病足溃疡的新型抗炎和抗氧化疗法
  • 批准号:
    10600900
  • 财政年份:
    2022
  • 资助金额:
    $ 51.29万
  • 项目类别:
Using a chemical biology approach to develop novel inhibitors of mitochondrial oxidative phosphorylation for the treatment of ovarian cancer
使用化学生物学方法开发用于治疗卵巢癌的新型线粒体氧化磷酸化抑制剂
  • 批准号:
    10260915
  • 财政年份:
    2022
  • 资助金额:
    $ 51.29万
  • 项目类别:
SymHeal: A novel therapy for treating non-healing diabetic ulcers
SymHeal:一种治疗不愈合糖尿病溃疡的新疗法
  • 批准号:
    10602837
  • 财政年份:
    2022
  • 资助金额:
    $ 51.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了